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the life cycle of nanomedicine
Thomas Faunce and Kathy Shats*
Nanotechnology is rapidly emerging as a transformational influence on many
industry sectors. This is particularly true of medicines and medical devices.
This article argues that, as policy interest in devising an appropriate
regulatory framework for nanotherapeutics escalates, it will be important for
public health to ensure that a broad life-cycle approach to both safety and
cost-effectiveness is adopted. It charts some of the most important issues
likely to be faced and begins to map how they can best be addressed.
INTRODUCTION
The term “nanotechnology” was first coined by Feynman in 1959.1 The nanotechnology industry since
then has boomed, with investment worldwide expected to reach US$1 trillion by 2015.2 The
technological impact of nanotechnology has been compared to that of the Industrial Revolution.3 It has
even been heralded as a possible solution to pollution and climate change in developed nations and
food and water problems in the developing world.4
Yet, as interest and promise in the industry grows, concerns regarding safety and societal
implications are rapidly emerging in academic literature and government, international and
non-governmental organisations (NGOs), as well as within the private sector. Some critics are calling
for a moratorium on all nanotechnology research, development and marketing until all the risks can be
assessed.5 Other critics have recommended a complete moratorium on production of nanomaterials.6
Their concerns are echoed by scientists, ethicists and scholars, as evidence of potential risks and
dangers emerges within an “ethical-legal void”.7 In 2004, an influential report by the United Kingdom
Royal Society and Royal Academy of Engineering became a catalyst for the debate on regulation of
nanotechnology.8 One area that seems to have received insufficient attention in these debates is
cost-effectiveness analysis, ensuring that the community receives real value for the money it spends on
presumptively innovative nanotechnology. This will be a particularly important concern in relation to
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medical applications of nanotechnology. This article argues that a broader approach to regulation of
nanotherapeutics needs to be taken than merely a focus on traditional safety issues.
REGULATING NANOTHERAPEUTICS SAFETY RISKS
One of the greatest regulatory challenges will lie in the risk assessment of nanotechnology generally,
and particularly in nanotherapeutics. Nanoparticles (NPs) pose new risks to health (both in the
manufacturing process and consumer use) and consequently to the environment. While there is a lack
of research and agreement regarding the effects of NPs on biological systems,9 it is generally accepted
that, due to the decrease in size, and consequent changes in surface area to volume ratio, NPs may
exhibit new and different properties to the equivalent substance on the macro level.10 As a result, NPs
are more toxic and reactive within biological systems.11 Issues of risk assessment arise in relation to
the manufacturing process, the use of nanotherapeutics in health care, and the environmental
consequences.
It is accepted that size has a significant impact on the toxicity to human health of any materials.
Many materials which are harmless in bulk have been known to become toxic to human health when
broken down into small particles.12 There is strong evidence that apparently non-toxic particles on a
fine or nano scale can cause inflammatory lung injury,13 and have toxic effects on cells and organs.14
It is easy to see why many commentators are concerned about “the possibility that NPs could become
the asbestos of the 21st century”.15
Risk assessment models must also consider the bioaccumulation and redistribution of NPs within
various organs and tissues. NPs between 20 and 50 nm have the potential to enter the central nervous
system and cells, while gold NPs are able to move through a mother’s placenta to the fetus.16
Concerns about the ability of NPs to cross the blood-brain barrier, as well as to accumulate in the
liver, have also been highlighted by numerous sources.17 There is also evidence that macrophages may
not recognise NPs smaller than 70 nm, allowing them access into the pulmonary interstitium.18 Gwinn
and Vallyathan reviewed the toxicity of ultrafine particles (UFPs) to human health and compared the
risks to NPs, concluding that “there is reason to suspect that NPs with size and surface characteristics
similar to UFPs are likely to cause diseases – some with a long latency”.19 The ability of NPs to pass
directly into the brain has also raised claims that, when combined with metals, NPs may cause
Alzheimer’s disease.20
In Australia, it is estimated that there are currently up to 700 workers who may be exposed to NPs
in some form, and it has been predicted that globally there will be two million workers employed in
nanotechnology-related industries by 2015.21
9 Australia, Senate Community Affairs References Committee, Report: Workplace Exposure to Toxic Dust (Commonwealth
Government, Canberra, May 2006), http://www.aph.gov.au/senate/committee/clac_ctte/toxic_dust/report/report.pdf viewed
21 April 2007, p 87.
10 UK Royal Society Report, n 8, p 36.
11 Nel et al, n 3 at 622.
12 Chan VSW, “Nanomedicine: An Unresolved Regulatory Issue” (2006) 46 Reg Toxic Pharm 218.
13 Oberdörster G, Toxicology of Airborne Environmental and Occupational Particles (University of Rochester), http://
www2.envmed.rochester.edu/envmed/tox/faculty/oberdoerster.html viewed 19 April 2007.
14 UK Royal Society Report, n 8, p 37.
15 Gwinn and Vallyathan, n 3 at 1818.
16 Chan, n 12 at 221.
17 Australia, Senate Community Affairs References Committee Report, n 9, p 88.
18 Oberdörster G, “Pulmonary Effects of Inhaled Ultrafine Particles” (2001) 74(1) Int Arch Occup Environ Health 1; Australia,
Senate Community Affairs References Committee Report, n 9, p 87.
19 Gwinn and Vallyathan, n 3 at 1824.
20 Australia, Senate Community Affairs References Committee Report, n 9, p 88.
21 Australia, Senate Community Affairs References Committee Report, n 9, p 86.
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The Australian Senate Community Affairs References Committee report on workplace exposure to
toxic dust outlines a number of key concerns about the impact of nanotechnology on workplace safety,
including the lack of methods to assess safety or to safeguard workers from exposure, as well as the
minimal investment in health and safety aspects of nanotechnology.22 The report discusses the views
of the Australian Institute of Occupational Hygienists (AIOH) and the Australian Manufacturing
Workers Union (AMWU) who express concern about the potential for skin penetration and inhalation
of NPs in the workplace, and make parallels with asbestos. Many submissions to the committee raised
this issue, and were particularly concerned about the long-term effects of NPs which may only
manifest after a long time. Dr Wiesner of Rice University has been quoted comparing the shape of
carbon nanotubes to asbestos fibres.23
Risk assessment of nanotechnology in health care
The use of nanotechnology in medicine is one of the most promising applications of this technology.
There is considerable research into a broad range of medical uses of NPs, including drug delivery,
gene therapy and medical imaging.24 While the risks of NPs in these types of medical applications will
overlap with the general toxicological risks identified earlier, it is possible to make more specific
predictions as certain parameters such as dosage, biodegradability and size are known and can be
controlled to some extent.
The dosage and concentration of NPs have a major influence on toxicity. Wilson discusses studies
that have shown pulmonary damage caused by carbon nanotubes in rats and mice, but comments on
the danger of attributing this exclusively to the hazards of NPs, as this was a very high dose study. She
notes that “high dose studies produce several possible exposure curves, and it is impossible to know
which dose curve is being mapped when a high dose is being extrapolated from”.25 At a low dosage,
some chemicals may be completely safe, but can have lethal effects at higher dosages. Wilson also
points out that defining a high or low dose is difficult due to the lack of data on exposure levels.26
Similar issues arise in relation to the size of the NPs, which can determine their fate in the human
body. Wilson compares studies of 1 nm and 5 nm particles, demonstrating considerable differences in
their disposition, and consequently health effects, within the human body.27
While most policy discussions of nanotechnology centre around the risks and potential for harm,
much of the medical literature discusses nanomedicine as a potentially safer alternative to current
options. For example, Gwinn and Vallyathan believe that “targeted encapsulated drug delivery using
NPs is more effective for improved bioavailability, minimal side effects, decreased toxicity to other
organs, and is less costly”.28 The use of NPs in gene therapy has also been seen as a much safer
method than viral vectors, which are currently the primary method of gene delivery. Chan notes that
“in theory, nanoparticles are less immunologically reactive than virus vectors and allow delivery of
large amount [sic] of genetic material with its large surface area to the target cells”.29
Hence, while there is need for more toxicology and safety research, a risk assessment of NPs in
nanomedicine needs to be seen in light of current technology, the dangers of which, while perhaps
more accepted, may still be very high. Lacerda et al discuss the fact that many fields of medicine, such
22 Australia, Senate Community Affairs References Committee Report, n 9, pp 88-89.
23 “Dangers Come in Small Particles”, Hazards Magazine (hazards.org), http://www.hazards.org/nanotech/safety.htm viewed
20 April 2007.
24 Lacerda L, Bianco A, Prato M and Kostarelos K, “Carbon Nanotubes as Nanomedicines: From Toxicology to Pharmacology”
(2006) 58 Adv Drug Deliv Rev 1460; Jin S and Ye K, “Nanoparticle-mediated Drug Delivery and Gene Therapy” (2007) 23
Biotechnol Prog 32; Chan, n 12.
25 Wilson RF, “Nanotechnology: The Challenge of Regulating Known Unknowns” (2006) J Law Med Eth 704 at 708.
26 Wilson, n 25 at 708.
27 Wilson, n 25 at 709.
28 Gwinn and Vallyathan, n 3 at 1819.
29 Chan, n 12 at 220.
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as oncology, rely on techniques known to be inherently dangerous, such as nuclear technology.30 The
side effects and dangers are assessed through toxicological studies, and the same should be done for
nanotherapeutics. The authors note that “such toxicological and pharmacological characterisation is
already part of the process of pharmaceutical development and approval, so nanomedicines should not
be considered more harmful than any of the cytotoxic drug molecules being developed”.31
Fate of nanoparticles: Environmental and ecological concerns
After consumer use (whether medical, cosmetic or technological), the eventual fate of NPs must also
be addressed. Although research on potential environmental hazards such as soil and water toxicity is
scarce, these risks have been identified and are an essential consideration in any cost-benefit analysis.
The UK Royal Society Report expressed concern over the lack of literature and study in this field, but
pointed to research on largemouth bass, in which NPs (fullerenes) were found to have translocated to
the brain, causing oxidative damage.32 As with other chemicals, NPs have the potential to enter the
food chain through degradation in the water or soil. The report identifies the sources of NPs in the
environment as waste streams from factories and laboratories, as well as the widespread use of
medicines and cosmetics containing NPs. The greatest source will come from the use of NPs in water
and soil treatment, which may have a significant impact on the ecosystem. However, the UK Royal
Society Report suggests that although much more research would be needed, it is possible that “any
negative impacts on ecosystems will be outweighed by the benefits of the clean up of contaminated
land and waters”.33
TOWARD A BROADER VIEW ON REGULATORY ISSUES FOR NANOTHERAPEUTICS
Although the potential risks of nanotechnology vary considerably, most commentators believe that
some form of regulation is needed, or at least that it is inevitable.34 Marchant and Sylvester argue that
“despite nanotechnology’s generally unfettered past, its future will, in large part, be determined by the
legal choices made in the next few years”. As it is almost universally acknowledged that public
acceptance will determine the fate of the nanotechnology industry,35 this must be considered before
implementing any particular regulatory scheme. As stated above, many believe that “the future of
nanomedicine depends on the degree to which nanotechnology as a whole garners wide-scale public
support”.36
As evidenced by experience with biotechnologies such as genetically modified (GM) foods and
gene therapy, public involvement in the safety and regulatory debate is crucial to secure confidence,
and hence the success of the technology. Mehta argues that GM foods failed to gain public support
because the public were not involved in the discussion of the risks and benefits of the technology.37
The benefits flowed primarily to the producers (through agricultural benefits such as herbicide
tolerance), while consumers were left with little tangible benefit and a lot of perceived risk. Some
authors have expressed concern that lack of government action and public engagement in
nanotechnology could have similar results, “where the technology becomes so stigmatized that the
public will not accept proof of its safety”.38
30 Lacerda et al, n 24 at 1461.
31 Lacerda et al, n 24 at 1461.
32 UK Royal Society Report, n 8, p 45.
33 UK Royal Society Report, n 8, p 47.
34 Marchant GE and Sylvester DJ, “Transnational Models Regulation of Nanotechnology” (2006) 34(4) J Law Med Eth 714.
35 Roco and Bainbridge, n 4 at 7.
36 Mehta M, “The Future of Nanomedicine Looks Promising, But Only if We Learn from the Past” (2004) 13(1)
Health Law Rev 16.
37 Mehta, n 36 at 16.
38 Marchant and Sylvester, n 34 at 717.
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These concerns carry significant weight. A recent survey showed that the public was more
concerned about the risks and implications of nanotechnology than were experts and industry.39 The
research also questioned whether companies were adequately addressing public concerns, particularly
when most lack risk-assessment methods to address the issues. This leads to a lack of trust in new
technologies, and the authors fear that unless this is remedied, any negative incident arising from
nanotechnology could have a severe and perhaps irreparable effect on public perception. This fear is
reflected throughout the literature. Mehta contends that unless the risks and benefits are openly
assessed and discussed, the technology will evolve in an unstable environment, in which any accident
could severely hinder the development of nanomedicine.40 Wilson illustrates this through a recent
example of the cleaning product “MagicNano” in Germany.41 The bathroom-cleaning product, which
claimed to contain nanoparticles, had to be recalled after just three days on the market when nearly 80
cases of severe respiratory problems were linked to its use. Although later it was found that the
problems were caused not by NPs but by larger particles, this incident nevertheless caused the public
to question the safety of nanotechnology. Similarly, as discussed earlier, many scientists, critics and
policy-makers are already drawing analogies between NPs and asbestos. This is an issue about which
the public is becoming very well informed and, without open discussion, any adverse links drawn to
nanotechnology could easily have a negative impact on public perception.
While some aspects of risk assessment will be specific to nanotherapeutics, many broader issues
such as workplace safety and environmental impacts cannot be ignored. Therefore, the regulation of
nanotherapeutics cannot be addressed in isolation from broader nanotechnology risk assessment and
regulatory issues. However, without more research regarding these issues, it is difficult to gauge the
impact of the use of NPs in medicine on, eg, the environment. As discussed in the UK Royal Society
Report, the use of nanotechnology in water and soil treatment could potentially be justified if the
benefits were found to outweigh the risks.42 In this case, the environmental impact of NPs from
medical applications would be significantly less, and the regulation of nanotherapeutics separately
may not be an issue. However, until further research is done, this cannot be assumed, and many
activist and environmental groups such as ETC and Friends of the Earth are calling for the
precautionary principle to be applied.43
Attempting to regulate nanotherapeutics separately also appears illogical in light of the cosmetic
industry. As Wilson points out, “While drugs face exacting scrutiny, cosmetics receive no
pre-marketing screening. The FDA does not have authority to directly recall a cosmetic that harms
consumers.”44 As there is some evidence that NPs have the potential to penetrate the skin, and as NPs
used in many cosmetic products may also enter the body, it would seem logical that the risks they pose
are similar to those posed by nanotherapeutics, or the OH&S issues in the manufacturing process.
Rejeski, of the Woodrow Wilson International Centre for Scholars, believes that our current
regulatory frameworks will not be able to keep pace with the speed of technological innovation.45 He
argues that “many of our environmental regulations were built on the assumption that industrial
39 Siegrist M, Wiek A, Hellend A and Kastenholz H, “Risks and Nanotechnology: The Public is More Concerned Than Experts
and Industry” (2007) 2 Nature Nanotechnology 67.
40 Mehta, n 36 at 17.
41 Wilson, n 25; or see “Has All the Magic Gone?”, The Economist, http://www.economist.com/science/displaystory.cfm?story_
id=6795430 viewed 21 April 2007.
42 UK Royal Society Report, n 8, p 47.
43 Australia, Senate Community Affairs References Committee Report, n 9, pp 89-90.
44 Wilson, n 25 at 708.
45 Rejeski D, “The Next Small Thing” (Environmental Law Institute) p 45, http://www.wilsoncenter.org/docs/staff/Rejeski_
nextsmall.pdf viewed 20 April 2007.
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production and associated pollution would stay put”.46 Wilson also discusses evidence showing that
current environmental laws will not be able to respond to the new risks posed by NPs.47
Many NGOs and interest groups are calling for a strict application of the precautionary principle,
based on the lack of research into the risks and social ramifications of this technology. Swiss Re, an
insurance company, has expressed concern that, as with asbestos, the effects of nanotechnology may
be latent, and may result in huge liability for the insurance sector.48 On this basis, it, too, calls for a
strict application of the precautionary principle. In its simplest form, this would shift the burden of
proof onto the manufacturers to prove the safety of the product. Marchant and Sylvester discuss the
problems arising from this approach. They point to a lack of consensus regarding the exact meaning of
the precautionary principle, noting that at least 19 different versions have been identified.49 They also
argue that no version actually addresses
Central risk management decisions such as: (i) What level of risk is acceptable? (ii) What early
indications of potential hazard are needed to trigger precaution? (iii) How much data must proponents
produce to demonstrate that a product or activity is sufficiently “safe” to proceed? (iv) How are costs
and risk tradeoffs factored in? (v) What type of action is required to satisfy the precautionary
principle?50
Without being able to specifically address these questions, no regulatory framework can be
established. Only the strictest formulation, which would ban all nanotechnology, could be applied
before more research is done. This would inevitably halt any development in the technology, and
potentially never allow the risks to be assessed.51
Bowman and Hodge discuss the differences between the regulatory approaches taken by the
United Kingdom and the United States.52 In response to the United Kingdom Royal Society Report,
the United Kingdom Government has taken a proactive approach, and is encouraging all relevant
regulatory bodies to assess any possible gaps in the system. Based on the report, the United Kingdom
has also accepted NPs as new chemicals, and is looking at new regulatory mechanisms to reflect this.
In contrast, the United States does not recognise this approach, and maintains that materials containing
NPs do not warrant different treatment, resulting in them being assessed as equivalent to conventional
products on the macro scale.53 This approach has been criticised, with the suggestion that the current
regulatory framework within the United States is inadequate to address nanotechnology.54
COST-EFFECTIVENESS AND REFERENCE PRICING IN THE REGULATION OF
NANOMEDICINE
Reference pricing is a government price reimbursement mechanism that compares a new
pharmaceutical on grounds of independent expert assessment of objectively demonstrated therapeutic
significance related to outcomes on its primary clinical indication, against already available products
and therapies in the same therapeutic group.55 Prices of all drugs in such a group are tied to that of the
46 Rejeski, n 45, p 47.
47 Wilson, n 25 at 707.
48 Australia, Senate Community Affairs References Committee Report, n 9, p 90.
49 Marchant and Sylvester, n 34 at 721.
50 Marchant and Sylvester, n 34 at 721.
51 Marchant and Sylvester, n 34 at 721.
52 Bowman DM and Hodge GA, “A Small Matter of Regulation: An International Review of Nanotechnology Regulation”
(2007) 8 Columbia Sci Technol Law Rev 1 at 18.
53 Bowman and Hodge, n 52 at 19.
54 Davies JC, Managing the Effects of Nanotechnology (Woodrow Wilson International Centre for Scholars, 2005),
http://www.wilsoncenter.org/events/docs/effectsnanotechfinal.pdf viewed 20 April 2007.
55 Ioannides-Demos L, Ibrahim J and McNeil J, “Reference-based Pricing Schemes: Effect on Pharmaceutical Expenditure,
Resource Utilisation and Health Outcomes: Review Article” (2002) 20(9) Pharmacoeconomics 577.
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lowest, or in some cases the average, price.56 The reference price does not become the market price
for all drugs in the same therapeutic class, but is a benchmark.57 Manufacturers can set prices higher
than the reference, but in doing so they need to genuinely compete in the open market against
equivalent lower-priced medicines. In this sense, reference pricing is an inherently pro-competitive
fiscal lever that assists governments to ensure that expensive new technologies that make claims of
innovation based on remarkable technical novelty are actually offering genuine benefit to the
community on hard clinical outcomes such as quality adjusted life years (not surrogate physiological
measures) when compared to existing marketed products.58
A regulatory technique such as reference pricing fulfils a blueprint for a sustainable global health
technology industry such as that set out in the Australian National Medicines Policy. The four
principles of the National Medicines Policy are:
• timely access to the medicines that Australians need, at a cost individuals and the community can
afford;
• medicines meeting appropriate standards of quality, safety and efficacy;
• quality use of medicines; and
• maintaining a responsible and viable medicines industry.59
A regulatory system for nanotherapeutics will need to ensure the preservation and enhancement of
fiscal levers that expertly value health technology innovation transparently and accountably against
scientific criteria of objectively demonstrated therapeutic significance. Particularly important in this
context will be the maintenance of reference pricing for those allegedly innovative nanomedicines that
are unable to prove greater efficacy or safety than any existing therapy (drug or otherwise).
This is why recent amendments to the National Health Act 1953 (Cth) fracturing the unitary PBS
formulary into an F1 category (for patented medicines) and F2 (for generics) (new ss 85AB and
85AC) should be repealed. Such amendments limit evidence-based reference pricing between those
categories and by creating the prior and almost unachievable standard of “interchangeable on an
individual patient basis” between two comparators (new s 101(3BA)), leave open the door to
escalating prices in Australia for patented nanomedicines.
CONCLUSION
Positive and negative aspects have characterised national and international regulatory models of
biotechnology regulation.60 National regulatory systems can be tailored to meet local social and
economic demands, allowing countries to experiment in order to find the most suitable model.
However, these approaches may ignore potential security risks, such as cross-border pollution or even
the possibility of an arms race. The GM food industry suffered significantly as a result of different
national regulatory schemes. The different social and legal issues within each country resulted in “a
substantial burden on GMO researchers and scientists to assure regulatory compliance in the
development, export, and use of GMO technologies”.61 It has been proposed that nanotechnology will
inevitably have to be regulated at an international level due to the global scope of the environmental,
security and economic issues.
56 Lipsy RJ, “Institutional Formularies: The Relevance of Pharmacoeconomic Analysis to Formulary Decisions” (1992) 1(4)
Pharmacoeconomics 265.
57 Jacobzone S, Pharmaceutical Policies in OECD Countries: Reconciling Social and Industrial Goals (OECD, Paris, 2000)
(DEELSA/ELSA/WD) 1.
58 Giuliani G, Selke G and Garattini L, “The German Experience in Reference Pricing” (1998) 44(1) Health Policy 73.
59 Commonwealth of Australia. National Medicines Policy, http://www.health.gov.au/internet/wcms/publishing.nsf/Content/
nmp-objectives-policy.htm viewed 6 February 2007.
60 Marchant and Sylvester, n 34.
61 Marchant and Sylverster, n 34 at 717.
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It also has been suggested that current international regulatory frameworks may be developed to
incorporate nanotechnology governance.62 Bowman and Hodge discuss the possible roles of the World
Trade Organisation (WTO) and the Organisation for Economic Cooperation and Development
(OECD) in international nanotechnology regulation. They conclude that while they will not provide a
complete system, “the OECD’s effort to establish guidelines (ie, forms of ‘soft law’) is likely to
become a foundation for any emerging consensus on global frameworks and codes of conduct”.63
Perhaps the best mechanism for ensuring a balance of public and private goods, and for
revitalising markets towards responsible sustainability, is an international treaty on health technology
safety and cost-effectiveness.64 Such a treaty could play a critical role in regulating the global
nanotherapeutics to ensure community value as well as sustainable profits.
62 Bowman and Hodge, n 52.
63 Bowman and Hodge, n 52 at 36.
64 Faunce TA, “Toward a Treaty on Safety and Cost-effectiveness of Pharmaceuticals and Medical Devices: Enhancing an
Endangered Global Public Good” (2006) 2 Globalization and Health 5.
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